Although only semiofficial, it’s anal cancer awareness day this Tuesday. We will be discussing a review article on chemoradiation for anal cancer this month for #radonc journal club:
Evolution and Management of Treatment-Related Toxicity in Anal Cancer. Surgical Oncol Clin N Am 2017;26:91-113
The article is a review that will provide good context on how treatment has evolved for this uncommon cancer. Thanks to John Vassallo at Surgical Clinics, the article is temporarily open access for the journal club this weekend.
Please join Ethan Ludmir at MD Anderson and colleagues as we discuss treatment toxicity and supportive care. Our chat will begin 6AM Central Standard Time on Saturday March 18 and carry through into Sunday. Scheduling a ‘live hour’ is still in the works; that’s my fault as I’m a little less organized than usual this month. Stay tuned to see if I get my act together in time!
Here are our topic questions:
T1. What does chemoradiation offer as an alternative to surgical toxicity in anal cancer?
T2. How has intensity modulated radiation therapy (IMRT) changes the toxicities of radiation?
T3. How has systemic therapy evolved, and what are the toxicities we see?
T4. What are the current supportive care issues that needs to be addressed during treatment and in years to come?
T4a. Any specific needs for certain patient populations?
T5. What are the key areas to address in the future with supportive care?
- Here are guidelines on how to sign up and participate
- Read our disclaimer for ways to keep it rewarding and professional. If you’re not ready, just lurk and tune into the conversation.
Any suggestions? Leave a comment or tweet us at @Rad_Nation. We look forward to having you join us!